MARKET

INKT

INKT

Mink Therapeutics, Inc.
NASDAQ
11.15
-0.17
-1.50%
After Hours: 10.83 -0.32 -2.83% 19:39 12/31 EST
OPEN
11.19
PREV CLOSE
11.32
HIGH
11.37
LOW
11.07
VOLUME
8.60K
TURNOVER
--
52 WEEK HIGH
76.00
52 WEEK LOW
4.560
MARKET CAP
52.34M
P/E (TTM)
-3.6749
1D
5D
1M
3M
1Y
5Y
1D
Ryvyl, NeoGenomics And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Benzinga · 12/30/2025 13:03
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Benzinga · 12/30/2025 12:05
Why Fonar Shares Are Trading Higher By Over 24%; Here Are 20 Stocks Moving Premarket
Benzinga · 12/30/2025 09:43
Weekly Report: what happened at INKT last week (1222-1226)?
Weekly Report · 12/29/2025 09:37
Weekly Report: what happened at INKT last week (1215-1219)?
Weekly Report · 12/22/2025 09:37
Weekly Report: what happened at INKT last week (1208-1212)?
Weekly Report · 12/15/2025 09:41
Weekly Report: what happened at INKT last week (1201-1205)?
Weekly Report · 12/08/2025 09:40
Weekly Report: what happened at INKT last week (1124-1128)?
Weekly Report · 12/01/2025 09:38
More
About INKT
MiNK Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. It is advancing a pipeline of both native and engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery. Its advanced product candidate, agenT-797, is an off-the-shelf, allogeneic, native iNKT cell therapy designed to provide transformative treatment options. AgenT-797 is an iNKT cell therapy that harnesses the dual power of innate and adaptive immunity. In addition, it is advancing a pipeline of allogeneic, engineered iNKT programs. Its two advanced preclinical engineered programs are MiNK-413, an IL-15 armored CAR-iNKT program targeting B cell maturation antigen (BCMA), and MiNK-215, an IL-15 armored tumor stromal targeting FAP-CAR-iNKT program.

Webull offers Mink Therapeutics Inc stock information, including NASDAQ: INKT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, INKT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading INKT stock methods without spending real money on the virtual paper trading platform.